TY - JOUR
T1 - Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary disease
AU - for the Non-Tuberculous Mycobacteriosis-Japan Research Consortium (NTM-JRC)
AU - Kimizuka, Yoshifumi
AU - Hoshino, Yoshihiko
AU - Nishimura, Tomoyasu
AU - Asami, Takahiro
AU - Sakakibara, Yumi
AU - Morimoto, Kozo
AU - Maeda, Shinji
AU - Nakata, Noboru
AU - Abe, Takayuki
AU - Uno, Shunsuke
AU - Namkoong, Ho
AU - Fujiwara, Hiroshi
AU - Funatsu, Yohei
AU - Yagi, Kazuma
AU - Fujie, Toshihide
AU - Ishii, Makoto
AU - Inase, Naohiko
AU - Iwata, Satoshi
AU - Kurashima, Atsuyuki
AU - Betsuyaku, Tomoko
AU - Hasegawa, Naoki
N1 - Funding Information:
This work was supported in part by Grants-in-Aid for Scientific Research (C) (25461178, 16K09941 and 16K09942) from the Japan Society for the Promotion of Science (http:// www.jsps.go.jp/english/index.html) for Y.H., N.H. and T.N., respectively. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2019 Kimizuka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2019/4
Y1 - 2019/4
N2 - Background There is no proven management for mild cases of Mycobacterium avium complex (MAC) pulmonary disease, who do not immediately receive treatment and are managed with observation alone, because its long term-natural course, factors predictive of deterioration, and the effect of treating the disease remain unclear. Thus, we sought to investigate the natural course of mild cases of MAC pulmonary disease. Methods We conducted a multicenter retrospective study. Sixty-five patients with mild MAC pulmonary disease in whom treatment was withheld for at least 6 months after diagnosis were retrospectively recruited after a review of 747 medical records. Longitudinal changes in clinical features were evaluated by using a mixed effects model. Results Mean follow-up was 6.9 ± 5.7 years. During the follow-up period, 15 patients (23%) required treatment and 50 (77%) were managed with observation alone. At diagnosis, 65 patients had nodular bronchiectatic disease without fibrocavitary lesions. Among clinical features, mean body mass index (BMI), forced expiratory volume in 1 second as percent of forced vital capacity (%FEV 1 ), nodular lung lesions, and bronchiectasis worsened significantly in the observation group during follow-up. In the treatment group, BMI, and % FEV 1 were stable, but bronchiectasis significantly worsened. At diagnosis, the polyclonal MAC infection rate in the treatment group was higher than that in the observation group. Other microbiological factors, such as insertion sequences, did not differ significantly between the groups. Conclusions Mild MAC pulmonary disease progresses slowly but substantially without treatment. Treatment prevents the deterioration of the disease but not the progression of bronchiectasis. Polyclonal MAC infection is a predictor of disease progression.
AB - Background There is no proven management for mild cases of Mycobacterium avium complex (MAC) pulmonary disease, who do not immediately receive treatment and are managed with observation alone, because its long term-natural course, factors predictive of deterioration, and the effect of treating the disease remain unclear. Thus, we sought to investigate the natural course of mild cases of MAC pulmonary disease. Methods We conducted a multicenter retrospective study. Sixty-five patients with mild MAC pulmonary disease in whom treatment was withheld for at least 6 months after diagnosis were retrospectively recruited after a review of 747 medical records. Longitudinal changes in clinical features were evaluated by using a mixed effects model. Results Mean follow-up was 6.9 ± 5.7 years. During the follow-up period, 15 patients (23%) required treatment and 50 (77%) were managed with observation alone. At diagnosis, 65 patients had nodular bronchiectatic disease without fibrocavitary lesions. Among clinical features, mean body mass index (BMI), forced expiratory volume in 1 second as percent of forced vital capacity (%FEV 1 ), nodular lung lesions, and bronchiectasis worsened significantly in the observation group during follow-up. In the treatment group, BMI, and % FEV 1 were stable, but bronchiectasis significantly worsened. At diagnosis, the polyclonal MAC infection rate in the treatment group was higher than that in the observation group. Other microbiological factors, such as insertion sequences, did not differ significantly between the groups. Conclusions Mild MAC pulmonary disease progresses slowly but substantially without treatment. Treatment prevents the deterioration of the disease but not the progression of bronchiectasis. Polyclonal MAC infection is a predictor of disease progression.
UR - http://www.scopus.com/inward/record.url?scp=85064898006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064898006&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0216034
DO - 10.1371/journal.pone.0216034
M3 - Article
C2 - 31022253
AN - SCOPUS:85064898006
SN - 1932-6203
VL - 14
JO - PloS one
JF - PloS one
IS - 4
M1 - e0216034
ER -